Cencora, Inc. (NYSE:COR) Shares Sold by Larson Financial Group LLC

Larson Financial Group LLC cut its position in shares of Cencora, Inc. (NYSE:COR) by 9.2% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 1,726 shares of the company’s stock after selling 174 shares during the quarter. Larson Financial Group LLC’s holdings in Cencora were worth $388,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Intellectus Partners LLC raised its holdings in Cencora by 6.6% during the fourth quarter. Intellectus Partners LLC now owns 3,260 shares of the company’s stock worth $732,000 after purchasing an additional 202 shares during the last quarter. AMF Tjanstepension AB increased its position in Cencora by 147.4% during the fourth quarter. AMF Tjanstepension AB now owns 79,207 shares of the company’s stock worth $17,799,000 after buying an additional 47,193 shares in the last quarter. Banco Santander S.A. purchased a new position in Cencora during the fourth quarter worth $821,000. Haven Private LLC purchased a new position in Cencora during the fourth quarter worth $753,000. Finally, Novus Advisors LLC purchased a new position in Cencora during the fourth quarter worth $225,000. 97.52% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research firms have weighed in on COR. Mizuho began coverage on Cencora in a research report on Wednesday, December 4th. They set an “outperform” rating and a $280.00 price target for the company. Wells Fargo & Company raised their price target on Cencora from $237.00 to $251.00 and gave the stock an “equal weight” rating in a research report on Wednesday, January 29th. JPMorgan Chase & Co. raised their price target on Cencora from $289.00 to $301.00 and gave the stock an “overweight” rating in a research report on Friday, January 24th. StockNews.com downgraded Cencora from a “buy” rating to a “hold” rating in a research report on Tuesday, March 4th. Finally, Evercore ISI lifted their price objective on Cencora from $270.00 to $280.00 and gave the company an “outperform” rating in a research report on Thursday, February 6th. Three investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $277.90.

Insider Activity at Cencora

In other Cencora news, CEO Robert P. Mauch sold 4,970 shares of the business’s stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $255.00, for a total transaction of $1,267,350.00. Following the transaction, the chief executive officer now owns 51,070 shares in the company, valued at $13,022,850. The trade was a 8.87 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Silvana Battaglia sold 1,678 shares of the business’s stock in a transaction dated Friday, December 20th. The stock was sold at an average price of $228.72, for a total value of $383,792.16. Following the transaction, the executive vice president now owns 20,329 shares in the company, valued at approximately $4,649,648.88. This represents a 7.62 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 11,648 shares of company stock worth $2,862,342. 10.80% of the stock is owned by insiders.

Cencora Price Performance

Shares of Cencora stock opened at $261.65 on Tuesday. Cencora, Inc. has a twelve month low of $214.77 and a twelve month high of $262.56. The stock has a market capitalization of $50.74 billion, a P/E ratio of 37.22, a PEG ratio of 1.31 and a beta of 0.51. The company has a current ratio of 0.92, a quick ratio of 0.54 and a debt-to-equity ratio of 16.40. The business’s fifty day moving average price is $245.08 and its 200 day moving average price is $238.54.

Cencora (NYSE:COR) last issued its earnings results on Wednesday, February 5th. The company reported $3.73 earnings per share for the quarter, beating analysts’ consensus estimates of $3.50 by $0.23. Cencora had a return on equity of 328.62% and a net margin of 0.46%. As a group, research analysts anticipate that Cencora, Inc. will post 15.37 earnings per share for the current year.

Cencora Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Monday, March 3rd. Investors of record on Friday, February 14th were issued a $0.55 dividend. This represents a $2.20 dividend on an annualized basis and a yield of 0.84%. The ex-dividend date was Friday, February 14th. Cencora’s payout ratio is currently 31.29%.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.